Lakefront Biotherapeutics | GLPG - Des Atouts





Des Atouts Changement Date
argenx SE USD 10.03B 1.35B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Biogen USD 32.09B 2.6B 2026-06
Genmab DKK 12.52B 139M 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
GRIFOLS EUR 20.09B 12M 2026-06
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Incyte USD 7.87B 533.53M 2026-06
Merck EUR 52.69B 383M 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
UCB EUR 18.16B 971M 2025-12
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06